<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802214</url>
  </required_header>
  <id_info>
    <org_study_id>IRB48889</org_study_id>
    <nct_id>NCT03802214</nct_id>
  </id_info>
  <brief_title>Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy</brief_title>
  <official_title>A Case-control Study to Evaluate the Immunoinflammatory Effect of Prior Exposure to Anti-TNF Therapy in Patients With Ulcerative Colitis Starting Vedolizumab Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF
      therapy in patients with ulcerative colitis starting vedolizumab therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammatory bowel disease (IBD)- ulcerative colitis (UC) and Crohn's disease (CD)- are
      chronic conditions of the gastrointestinal tract. Treatment generally consists of
      immunosuppression to modify the dysregulated immune responses. Vedolizumab, an inhibitor of
      α4β7, is a highly effective therapy for treating IBD, that minimized adverse effects through
      its gut selective inhibition of lymphocyte trafficking. However, the mechanism of action
      remains incompletely characterized especially in those previously treated to other biologics
      and why some patients are either vedolizumab non-responders or fail to respond over time. We
      would like to address the question whether anti-TNF non-responders as well as those that
      either do not respond or fail overtime to respond to vedolizumab identifies a specific
      population with difficult to treat disease that have alternate trafficking patterns and
      whether prior exposure to anti-TNF alters the mucosal immune responses, and/or trafficking
      patterns when compared to anti-TNF naive patients that may help explain impaired response to
      vedolizumab induction therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells)</measure>
    <time_frame>changes from enrollment to end of treatment (week 14)</time_frame>
    <description>Analysis of blood and tissue leukocytes (T cells, B cells and Dendritic cells) in patients with and without prior anti-TNF exposure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the serum and tissue concentrations of inflammatory markers (interleukins)</measure>
    <time_frame>changes from enrollment to end of treatment (week 14)</time_frame>
    <description>Analysis of the serum and tissue concentrations of inflammatory markers (interleukins) in vedolizumab responders versus non-responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the serum and tissue concentrations of vedolizumab</measure>
    <time_frame>changes from enrollment to end of treatment (week 14)</time_frame>
    <description>Analysis of the serum and tissue concentrations of vedolizumab in patients with and without prior anti-TNF exposure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>vedolizumab-UC-naïve to TNF-antagonist</arm_group_label>
    <description>standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vedolizumab-UC- previous TNF-antagonist</arm_group_label>
    <description>standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab</intervention_name>
    <description>standard vedolizumab induction (300mg IV at week 0, 2, 6)</description>
    <arm_group_label>vedolizumab-UC- previous TNF-antagonist</arm_group_label>
    <arm_group_label>vedolizumab-UC-naïve to TNF-antagonist</arm_group_label>
    <other_name>Entyvio</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      collection of blood and tissue specimens for immunology and drug assessment
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        clinical indication for biologic therapy, adult patients (&gt;18) with the diagnosis of
        inflammatory bowel disease (Ulcerative Colitis) who are naive or failed anti-TNF therapy
        previously.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients (&gt;18 years old)

          -  clinical diagnosis of inflammatory bowel disease (Ulcerative Colitis)

          -  clinical indication for biologic therapy

          -  naive or failed anti-TNF therapy previously

        Exclusion Criteria:

          -  patients allergic or intolerant to vedolizumab,

          -  past use of vedolizumab;

          -  patient unable to give consent to enter the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida Habtezion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aida Habtezion, MD</last_name>
    <phone>650-723-5488</phone>
    <email>aidah@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reena Khanna, MD</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>34945</phone_ext>
    <email>rkhanna3@uwo.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gubatan, MD</last_name>
      <phone>650-736-5555</phone>
      <email>jgubatan@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, Atreya R. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. Gut. 2019 May;68(5):814-828. doi: 10.1136/gutjnl-2017-315671. Epub 2018 May 30.</citation>
    <PMID>29848778</PMID>
  </reference>
  <reference>
    <citation>Boden EK, Shows DM, Chiorean MV, Lord JD. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Dig Dis Sci. 2018 Sep;63(9):2419-2429. doi: 10.1007/s10620-018-4924-8. Epub 2018 Jan 25.</citation>
    <PMID>29372476</PMID>
  </reference>
  <reference>
    <citation>Suzawa K, Kobayashi M, Sakai Y, Hoshino H, Watanabe M, Harada O, Ohtani H, Fukuda M, Nakayama J. Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. Am J Gastroenterol. 2007 Jul;102(7):1499-509. Epub 2007 Apr 24.</citation>
    <PMID>17459027</PMID>
  </reference>
  <reference>
    <citation>Kobayashi M, Hoshino H, Masumoto J, Fukushima M, Suzawa K, Kageyama S, Suzuki M, Ohtani H, Fukuda M, Nakayama J. GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. Inflamm Bowel Dis. 2009 May;15(5):697-706. doi: 10.1002/ibd.20827.</citation>
    <PMID>19067429</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.</citation>
    <PMID>23964933</PMID>
  </reference>
  <reference>
    <citation>Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.</citation>
    <PMID>23964932</PMID>
  </reference>
  <reference>
    <citation>Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202. doi: 10.1111/apt.13243. Epub 2015 May 20. Erratum in: Aliment Pharmacol Ther. 2015 Nov;42(9):1135.</citation>
    <PMID>25996351</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Aida Habtezion</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will share the data through the publication of results. Individual participant data was not promised to be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

